A5055374861- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Urological Disorders and Treatments
- Prostate Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Renal cell carcinoma treatment
- Urinary Tract Infections Management
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Ureteral procedures and complications
- Cancer Research and Treatments
- Urinary Bladder and Prostate Research
- Tissue Engineering and Regenerative Medicine
- Urologic and reproductive health conditions
- Esophageal Cancer Research and Treatment
- Pediatric Urology and Nephrology Studies
- Healthcare Policy and Management
- Immunotherapy and Immune Responses
- Renal and related cancers
- Colorectal Cancer Screening and Detection
- Colorectal Cancer Surgical Treatments
- Genetic factors in colorectal cancer
- Infectious Disease Case Reports and Treatments
- Multiple and Secondary Primary Cancers
- Ferroptosis and cancer prognosis
Rush University
2024-2025
Rush University Medical Center
2023-2025
NYU Langone Health
2019-2024
Allina Health
2024
University of Minnesota
2024
EpiVax (United States)
2019-2024
Providence College
2019-2024
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2020-2023
Urology Associates
2019-2023
New York University
2019-2023
Previous studies have demonstrated familial clustering of prostate cancer. To define the nature this aggregation and to assess whether Mendelian inheritance can explain cancer clustering, proportional hazards segregation analyses were performed on 691 families ascertained through a single proband. The revealed that two factors, early age at onset disease in proband multiple affected family members, important determinants risk these families. Furthermore, be best explained by autosomal...
Abstract A case‐control study was performed to estimate the relative risk of developing prostate cancer for men with a positive family history. Extensive pedigrees were obtained on 691 and 640 spouse controls. Fifteen percent cases but only 8% controls had father or brother affected ( P < .001). Men twice as likely develop no relatives affected. In addition, there trend increasing number members such that two three first degree five 11–fold increased cancer. Recognizing 9–10% U.S. will in...
Abstract Muscle-invasive urothelial bladder cancer is a common malignancy with poor outcomes for which immune checkpoint blockade now showing promise. Despite clinical activity of PD-1/PD-L1–targeted therapy in this disease, most patients do not benefit and resistance mechanisms remain unknown. The non–T-cell-inflamed tumor microenvironment correlates prognosis to immunotherapies. In study, we determined tumor-oncogenic pathways correlating T-cell exclusion. We first establish report that...
Study Type – Therapy (case series) Level of Evidence 4 What’s known on the subject? and What does study add? Accurate preoperative staging for upper‐tract urothelial carcinoma (UTUC) lesions is presently limited. Urinary cytology has shown promise characterizing pathological features bladder cancer. The role UTUC at present poorly defined. In this large multi‐institutional cohort patients, urinary was limited in its ability to accurately predict grade stage lesions. Selective ureteral...
Open AccessJournal of UrologyAdult Urology5 May 2024Efficacy Intravesical Nadofaragene Firadenovec for Patients with BCG-Unresponsive Non–muscle Invasive Bladder Cancer: 5 Year Follow-Up from a Phase 3 Trial Vikram M. Narayan, Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella, Ashish Kamat, Trinity J. Bivalacqua, Jeffrey S. Montgomery, Seth P. Lerner, Joseph E. Busby, Michael Poch, Paul L. Crispen, Gary Steinberg, Anne K. Schuckman, Tracy Downs,...
We assess the efficacy and safety of intravesical valrubicin for treatment carcinoma in situ patients with failure or recurrence after bacillus Calmette-Guerin (BCG) who otherwise would have undergone cystectomy. Total anthracycline recovery urine samples obtained within 24 hours administration was assessed a subset patients.A total 90 recurrent failed multiple prior courses therapy, including at least 1 course BCG, participated this open label, noncomparative study. Each patient received 6...
Introduction Retrospective studies suggest that p53 alteration is prognostic for recurrence in patients with urothelial bladder cancer and predictive benefit from combination methotrexate, vinblastine, doxorubicin, cisplatin (MVAC) adjuvant chemotherapy. Patients Methods pT1/T2N0M0 disease whose tumors demonstrated ≥ 10% nuclear reactivity on centrally performed immunohistochemistry were offered random assignment to three cycles of MVAC versus observation; p53-negative observed. By using a...
PURPOSE: To prospectively evaluate in a multicenter randomized trial the antitumor activity of CD8 + tumor-infiltrating lymphocytes (TILs) combination with low-dose recombinant interleukin-2 (rIL-2), compared rIL-2 alone, after radical nephrectomy metastatic renal cell carcinoma patients. PATIENTS AND METHODS: Between December 1994 and March 1997, 178 patients resectable primary tumors were enrolled at 29 centers United States Europe. Patients underwent total nephrectomy, recovered, to...
BACKGROUND Women have disproportionately higher mortality rates relative to incidence for bladder cancer. Multiple etiologies been proposed, including delayed diagnosis and treatment. Guidelines recommend ruling out malignancy in men women presenting with hematuria. This study sought determine the difference timing from presentation hematuria of cancer versus men. METHODS is a retrospective population‐based examining cancer, based on data MarketScan databases, which include enrollees more...
No AccessJournal of UrologyAdult Urology1 May 2018Efficacy and Safety Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance Bladder Cancer: A Phase III, Comparative, Multicenter Studyis corrected byERRATUM Siamak Daneshmand, Sanjay Patel, Yair Lotan, Kamal Pohar, Edouard Trabulsi, Michael Woods, Tracy Downs, William Huang, Jeffrey Jones, O’Donnell, Trinity Bivalacqua, Joel DeCastro, Gary Steinberg, Ashish Kamat, Matthew Resnick, Badrinath Konety, Mark Schoenberg, J....
At the most recent Genitourinary Cancers Symposium in Orlando February 2015, a task force was organized to discuss issues trial design non-muscle invasive bladder cancer. Our aim provide further clarification regarding disease states following treatment of patients with intravesical BCG and determine what events constitute progression any for cancer (NMIBC). The panelists were asked address number specific Tasks, enumerated below.
Non‐muscle‐invasive bladder cancer (NMIBC) is the most common form of cancer, with frequent recurrences and risk progression. Risk‐stratified treatment surveillance protocols are often used to guide management. In 2017, BJUI reviewed guidelines on NMIBC from four major organizations: American Urological Association/Society Oncology, European Association Urology, National Comprehensive Cancer Network, Institute for Health Care Excellence. The present update will review changes in broadly...
<h3>Background</h3> Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivolumab and ipilimumab have recently shown a survival benefit the first-line metastatic setting. To date, there been no reports on response of cancer to modern immunotherapy. We report remarkable an advanced tumor thrombus combined immunotherapy which facilitated...
Immune checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma. In cisplatin-eligible muscle-invasive bladder cancer (MIBC), cisplatin-based neoadjuvant chemotherapy (NAC) before radical cystectomy improves overall survival. Tumor PD-L1 expression increases in MIBC after NAC, suggesting potential synergy combining PD1/PD-L1 NAC. IDO1 is overexpressed and associated poor outcomes. Linrodostat mesylate (BMS-986205) – a selective, potent, oral...